Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
RESEARCH TOOLSreports
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.72Last Year’s EPS
1.04Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -9.72%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strategic partnerships, especially for key products such as Primatene MIST and BAQSIMI. However, challenges such as decreasing glucagon sales, reduced gross margins, and increased competition were notable. The sentiment is balanced with optimism in pipeline developments countered by competitive and margin pressures.Company Guidance
During Amphastar Pharmaceuticals' fourth quarter earnings call, the company provided guidance for 2025, highlighting several key metrics and strategic initiatives. The company reported 2024 revenues of $732 million, reflecting a 14% increase from the prior year, with fourth-quarter sales reaching $186 million, a 5% year-over-year growth. Primatene MIST, a cornerstone product, achieved $102 million in sales, up 14% from 2023. Amphastar anticipates high single-digit growth for Primatene MIST in 2025, supported by an expanded physician sampling program. Meanwhile, BAQSIMI, integrated into their diabetes franchise, saw sales grow by 12% at the factory level, contributing $41.8 million to net product sales, and is expected to see high single-digit unit growth following a 3% price increase. The collaboration with MannKind is set to enhance BAQSIMI's market reach. However, glucagon sales declined by 5% to $108 million due to competitive pressures, with further declines expected. The company remains optimistic about launching two new products from their pipeline in 2025, with four key products under regulatory review, including AMP-002, AMP-007, AMP-015, and AMP-018. Amphastar projects flat sales for 2025, with a return to double-digit growth in 2026, as the company navigates pricing pressures and competition. Gross margins are expected to decrease due to changes in sales dynamics and increased costs, while R&D and capital expenditures are set to rise with a focus on expanding their manufacturing capacity and advancing their insulin portfolio.Strong Revenue Growth
Achieved revenues of $732 million for fiscal year 2024, a 14% increase compared to the prior year. Fourth quarter revenue was $186 million, marking a 5% year-over-year growth.
Primatene MIST Sales Milestone
Primatene MIST reached annual sales of $102 million, representing a 14% increase from 2023, surpassing the $100 million goal set three years ago.
Strategic Partnership with MannKind
A new strategic partnership with MannKind to promote BAQSIMI, expanding sales reach and strengthening position in the diabetes care market.
Pipeline and Regulatory Developments
Optimistic about the potential approval of 4 key products in 2025, including AMP-002, AMP-007, AMP-015, and AMP-018, marking progress in the regulatory pipeline.
---
AMPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $31.49 | $28.43 | -9.72% |
| Nov 06, 2024 | $53.40 | $46.09 | -13.69% |
| Aug 07, 2024 | $38.89 | $44.06 | +13.29% |
| May 08, 2024 | $42.21 | $42.43 | +0.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amphastar Pharmaceuticals (AMPH) report earnings?
Amphastar Pharmaceuticals (AMPH) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Amphastar Pharmaceuticals (AMPH) earnings time?
Amphastar Pharmaceuticals (AMPH) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMPH EPS forecast?
AMPH EPS forecast for the fiscal quarter 2025 (Q1) is 0.72.
---